spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  tuberous sclerosis 

 HSMN NewsFeed - 4 Apr 2022
FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2020
BioPharmX Corporation Urges Stockholders to Vote Now on Proposed Merger with Timber Pharmaceuticals
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 28 Dec 2017
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Jun 2016
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
tuberous sclerosis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.